Sodium‐glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study
Brain and Behavior · 2024
DOI: 10.1002/brb3.3624 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2024. Verfasst von Jinxin Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, China. Hauptthemen laut MEDLINE: Mendelian Randomization Analysis, Sodium-Glucose Transporter 2 Inhibitors, Polymorphism, Single Nucleotide, Neurodegenerative Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
This study aims to evaluate the effects of sodium‐glucose cotransporter 1 inhibitors (SGLT1i) and sodium‐glucose cotransporter 2 inhibitors (SGLT2i) on neurodegenerative disorders and to investigate the role of hemoglobin A1c (HbA1c) levels.
Methods
Utilizing drug target Mendelian randomization, we employed single nucleotide polymorphisms (SNPs) proximal to the SLC5A1 and SLC5A2 genes to analyze the influence of SGLT1i and SGLT2i on Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), frontotemporal dementia (FTD), Lewy body dementia (LBD), and amyotrophic lateral sclerosis (ALS), with type 2 diabetes (T2D) as a positive control. An additional analysis examined the impact of HbA1c levels on the same disorders.
Results
SGLT1i exhibited a significant association with decreased risk for ALS and MS. Conversely, SGLT2i were linked to an increased risk of AD, PD, and MS. Elevated HbA1c levels, independent of SGLT1 and SGLT2 effects, were associated with an increased risk of PD. Sensitivity analyses supported the robustness of these findings.
Conclusion
Our study suggests that SGLT1i may confer protection against ALS and MS, whereas SGLT2i could elevate the risk of AD, PD, and MS. Additionally, elevated HbA1c levels emerged as a risk factor for PD. These findings underscore the importance of personalized approaches in the utilization of SGLT inhibitors, considering their varying impacts on the risks of neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, China.
ORCID-Profile: Jinxin Liu, Yankun Shao
Zitieren
APA
Liu, J., Shi, X., & Shao, Y. (2024). Sodium‐glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study. Brain and Behavior. https://doi.org/10.1002/brb3.3624
Vancouver
Liu J, Shi X, Shao Y. Sodium‐glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study. Brain and Behavior. 2024. doi:10.1002/brb3.3624
BibTeX
@article{Liu2024,
author = {Liu, Jinxin and Shi, Xinxiu and Shao, Yankun},
title = {Sodium‐glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study},
journal = {Brain and Behavior},
year = {2024},
doi = {10.1002/brb3.3624}
}
EUVIMED